These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 31926283)

  • 1. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Pássaro L; Cantón R;
    FEMS Microbiol Lett; 2021 Aug; 368(15):. PubMed ID: 34347078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
    Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
    Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
    Hernández-García M; García-Castillo M; García-Fernández S; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Romano J; Pássaro L; Paixão L; López-Mendoza D; Díaz-Regañón J; Cantón R;
    J Antimicrob Chemother; 2021 Jan; 76(2):370-379. PubMed ID: 33099623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
    Lob SH; Kazmierczak KM; Chen WT; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2022 Jun; 29():527-533. PubMed ID: 34896336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
    Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
    Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
    Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.